Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
详细信息 查看全文
- 作者：Hé ; lè ; ne Salmon1 ; 2 ; 3 ; Juliana Idoyaga5 ; Adeeb Rahman4 ; Marylè ; ne Leboeuf1 ; 2 ; 3 ; Romain Remark2 ; 3 ; Stefan Jordan1 ; 2 ; 3 ; Maria Casanova-Acebes1 ; 2 ; 3 ; Makhzuna Khudoynazarova1 ; 2 ; 3 ; Judith Agudo2 ; 3 ; 4 ; Navpreet Tung1 ; 2 ; 3 ; Svetoslav Chakarov9 ; Christina Rivera1 ; 2 ; 3 ; Brandon Hogstad1 ; 2 ; 3 ; Marcus Bosenberg6 ; Daigo Hashimoto7 ; Sacha Gnjatic2 ; 3 ; Nina Bhardwaj2 ; 3 ; Anna Karolina Palucka8 ; Brian D. Brown2 ; 3 ; 4 ; Joshua Brody2 ; 3 ; Florent Ginhoux9 ; Miriam Merad1 ; 2 ; 3 ; miriam.merad@mssm.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Immunity
- 出版年：2016
- 出版时间：19 April 2016
- 年：2016
- 卷：44
- 期：4
- 页码：924-938
- 全文大小：3979 K
文摘
- •
CD103+ DCs are uniquely able to transport intact antigens to the TdLN and prime CD8+ T cells
- •
CD103+ DCs are required to induce anti-PD-L1-Ab-mediated anti-tumor immunity
- •
Combined FLT3L and poly I:C therapy induces expansion and activation of CD103+ DC progenitors in tumors
- •
Combined FLT3L and poly I:C therapy enhances tumor responses to BRAF and checkpoint blockade